Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells

Toxicology Letters

Volumn 216, Issue 2-3, 2013, Pages 159-170

  Ferreira, Patrícia Silva ^a   Nogueira, Tiago Bernandes ^a   Costa, Vera Marisa ^a   Branco, Paula Sério ^b   Ferreira, Luísa Maria ^b   Fernandes, Eduarda ^a   Bastos, Maria Lourdes ^a   Meisel, Andreas ^c   Carvalho, Félix ^a   Capela, João Paulo ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b DEPARTAMENTO DE QUÍMICA   (Portugal)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

" Ecstasy"; Methyldopamine; N acetylcysteine (NAC); N Methyl methyldopamine; Neurotoxicity; SH SY5Y cells

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETYLCYSTEINE; ALPHA METHYLDOPAMINE; ANTIOXIDANT; BUTHIONINE SULFOXIMINE; CASPASE 3; CATECHOL DERIVATIVE; DOPAMINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; N METHYL ALPHA METHYLDOPAMINE; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOIC ACID; TIRON; UNCLASSIFIED DRUG; VANOXERINE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; METABOLITE; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1,2-DIHYDROXYBENZENE-3,5-DISULFONIC ACID DISODIUM SALT; ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE, TUMOR; DIPEPTIDES; DOPAMINERGIC NEURONS; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; GLUTATHIONE; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXICITY SYNDROMES; PIPERAZINES;

ANIMALIA; MEDA;

EID: 84871546317     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.11.015     Document Type: Article

References (54)

1. Aguirre P., Valdes P., Aracena-Parks P., Tapia V., Nunez M.T. Upregulation of gamma-glutamate-cysteine ligase as part of the long-term adaptation process to iron accumulation in neuronal SH-SY5Y cells. American Journal of Physiology. Cell Physiology 2007, 292:C2197-C2203.
2. Bachmann R.F., Wang Y., Yuan P., Zhou R., Li X., Alesci S., Du J., Manji H.K. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. International Journal of Neuropsychopharmacology 2009, 12:805-822.
3. Bai F., Lau S.S., Monks T.J. Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chemical Research in Toxicology 1999, 12:1150-1157.
4. Battaglia G., Yeh S.Y., O'Hearn E., Molliver M.E., Kuhar M.J., De Souza E.B. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics 1987, 242:911-916.
5. Brown J.M., Gouty S., Iyer V., Rosenberger J., Cox B.M. Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. Journal of Neurochemistry 2006, 98:495-505.
6. Cao Z., Hallur S., Qiu H.Z., Peng X., Li Y. Induction of endogenous glutathione by the chemoprotective agent, 3H-1,2-dithiole-3-thione, in human neuroblastoma SH-SY5Y cells affords protection against peroxynitrite-induced cytotoxicity. Biochemical and Biophysical Research Communications 2004, 316:1043-1049.
7. Capela J.P., Carmo H., Remião F., Bastos M., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Molecular Neurobiology 2009, 39:210-271.
8. Capela J.P., Macedo C., Branco P.S., Ferreira L.M., Lobo A.M., Fernandes E., Remiao F., Bastos M.L., Dirnagl U., Meisel A., Carvalho F. Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 2007, 146:1743-1757.
9. Capela J.P., Meisel A., Abreu A.R., Branco P.S., Ferreira L.M., Lobo A.M., Remião F., Bastos M.L., Carvalho F. Neurotoxicity of ecstasy metabolites in rat cortical neurons, and influence of hyperthermia. Journal of Pharmacology and Experimental Therapeutics 2006, 316:53-61.
10. Capela J.P., Ruscher K., Lautenschlager M., Freyer D., Dirnagl U., Gaio A.R., Bastos M.L., Meisel A., Carvalho F. Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia. Neuroscience 2006, 139:1069-1081.
11. Carvalho M., Remião F., Milhazes N., Borges F., Fernandes E., Monteiro M.C., Gonçalves M.J., Seabra V., Amado F., Carvalho F., Bastos M.L. Metabolism Is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chemical Research in Toxicology 2004, 17:623-632.
12. Chae M., Rhee G.S., Jang I.S., Kim K., Lee J.H., Lee S.Y., Kim M., Yang J., Park J., Lee S.H. ATG5 expression induced by MDMA (ecstasy), interferes with neuronal differentiation of neuroblastoma cells. Molecules and Cells 2009, 27:571-575.
13. Cheung Y.-T., Lau W.K.-W., Yu M.-S., Lai C.S.-W., Yeung S.-C., So K.-F., Chang R.C.-C. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 2009, 30:127-135.
14. Chu T., Kumagai Y., DiStefano E.W., Cho A.K. Disposition of methylenodioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochemical Pharmacology 1996, 51:789-796.
15. Commins D.L., Vosmer G., Virus R.M., Woolverton W.L., Schuster C.R., Seiden L.S. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. Journal of Pharmacology and Experimental Therapeutics 1987, 241:338-345.
16. Costa V.M., Silva R., Ferreira L.M., Branco P.S., Carvalho F., Bastos M.L., Carvalho R.A., Carvalho M., Remião F. Oxidation process of adrenaline in freshly isolated rat cardiomyocytes: formation of adrenochrome, quinoproteins, and GSH adduct. Chemical Research in Toxicology 2007, 20:1183-1191.
17. Easton N., Fry J., O'Shea E., Watkins A., Kingston S., Marsden C.A. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Research 2003, 987:144-154.
18. Erives G.V., Lau S.S., Monks T.J. Accumulation of neurotoxic thioether metabolites of 3,4-({+/-})-methylenedioxymethamphetamine in rat brain. Journal of Pharmacology and Experimental Therapeutics 2008, 324:284-291.
19. Escobedo I., O'Shea E., Orio L., Sanchez V., Segura M., de la Torre R., Farre M., Green A.R., Colado M.I. A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. British Journal of Pharmacology 2005, 144:231-241.
20. Escubedo E., Abad S., Torres I., Camarasa J., Pubill D. Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity. Neurochemistry International 2011, 58:92-101.
21. Esteban B., O'Shea E., Camarero J., Sanchez V., Green A.R., Colado M.I. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 2001, 154:251-260.
22. Felim A., Herrera G., Neudörffer A., Blanco M., O'Connor J.-E., Largeron M. Synthesis and in vitro cytotoxicity profile of the R-enantiomer of 3,4-dihydroxymethamphetamine (R-(-)-HHMA): comparison with related catecholamines. Chemical Research in Toxicology 2010, 23:211-219.
23. Goni-Allo B., Ó Mathúna B., Segura M., Puerta E., Lasheras B., de la Torre R., Aguirre N. The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology 2008, 197:263-278.
24. Granado N., O'Shea E., Bove J., Vila M., Colado M.I., Moratalla R. Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. Journal of Neurochemistry 2008, 107:1102-1112.
25. Hiramatsu M., Kumagai Y., Unger S.E., Cho A.K. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. Journal of Pharmacology and Experimental Therapeutics 1990, 254:521-527.
26. Jia Z., Misra B.R., Zhu H., Li Y., Misra H.P. Upregulation of cellular glutathione by 3H-1,2-dithiole-3-thione as a possible treatment strategy for protecting against acrolein-induced neurocytotoxicity. Neurotoxicology 2009, 30:1-9.
27. Jiang Y., Pei L., Li S., Wang M., Liu F. Extracellular dopamine induces the oxidative toxicity of SH-SY5Y cells. Synapse 2008, 62:797-803.
28. Johnson E., O'Callaghan J., Miller D. Brain concentrations of d-MDMA are increased after stress. Psychopharmacology 2004, 173:278-286.
29. Jones D.C., Duvauchelle C., Ikegami A., Olsen C.M., Lau S.S., de la Torre R., Monks T.J. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. Journal of Pharmacology and Experimental Therapeutics 2005, 313:422-431.
30. Kolbrich E.A., Goodwin R.S., Gorelick D.A., Hayes R.J., Stein E.A., Huestis M.A. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Therapeutic Drug Monitoring 2008, 30:320-332.
31. Lim H.K., Foltz R.L. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chemical Research in Toxicology 1988, 1:370-378.
32. Logan B.J., Laverty R., Sanderson W.D., Yee Y.B. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. European Journal of Pharmacology 1988, 152:227-234.
33. Luchtman D.W., Song C. Why SH-SY5Y cells should be differentiated. Neurotoxicology 2010, 31:164-165.
34. Macedo C., Branco P., Ferreira L., Lobo A., Capela J.P., Fernandes E., Bastos M.L., Carvalho F. Synthesis and cyclic voltammetry studies of 3,4-methylenedioxymethamphetamine (MDMA) main human metabolites. Journal of Health Science 2007, 53:31-42.
35. Milhazes N., Cunha-Oliveira T., Martins P., Garrido J., Oliveira C., Cristina R., Borges F. Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine (ecstasy) and its metabolites on undifferentiated PC12 cells: a putative structure-toxicity relationship. Chemical Research in Toxicology 2006, 19:1294-1304.
36. Miller D.B., O'Callaghan J.P. The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Molecular Neurobiology 1995, 11:177-192.
37. Miller R.T., Lau S.S., Monks T.J. Effects of intracerebroventricular administration of 5-(Glutathion-S-yl)-α-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. Chemical Research in Toxicology 1996, 9:457-465.
38. Miller R.T., Lau S.S., Monks T.J. 2,5-bis-(Glutathion-S-yl)-α-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. European Journal of Pharmacology 1997, 323:173-180.
39. Mueller M., Peters F.T., Ricaurte G.A., Maurer H.H. Liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in rat brain. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2008, 874:119-124.
40. Pizarro N., Farre M., Pujadas M., Peiro A.M., Roset P.N., Joglar J., de la Torre R. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metabolism and Disposition: The Biological Fate of Chemicals 2004, 32:1001-1007.
41. Pontes H., Sousa C., Silva R., Fernandes E., Carmo H., Remiao F., Carvalho F., Bastos M.L. Synergistic toxicity of ethanol and MDMA towards primary cultured rat hepatocytes. Toxicology 2008, 254:42-50.
42. Presgraves S.P., Ahmed T., Borwege S., Joyce J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotoxicity Research 2004, 5:579-598.
43. Ricaurte G.A., Yuan J., McCann U.D. (±)3,4-Methylenedioxymethamphetamine (ecstasy)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000, 42:5-10.
44. Satoh T., Lipton S.A. Redox regulation of neuronal survival mediated by electrophilic compounds. Trends in Neurosciences 2007, 30:37-45.
45. Schmidt C.J., Levin J.A., Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochemical Pharmacology 1987, 36:747-755.
46. Segura M., Ortuño J., Farré M., McLure J.A., Pujadas M., Pizarro N., Llebaria A., Joglar J., Roset P.N., Segura J., de la Torre R. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chemical Research in Toxicology 2001, 14:1203-1208.
47. Shavali S., Sens D.A. Synergistic neurotoxic effects of arsenic and dopamine in human dopaminergic neuroblastoma SH-SY5Y cells. Toxicological Sciences 2008, 102:254-261.
48. Silva R., Boldt S., Costa V.M., Carmo H., Carvalho M., Carvalho F., Bastos M.L., Lemos-Amado F., Remião F. Evaluation of GSH adducts of adrenaline in biological samples. Biomedical Chromatography 2007, 21:670-679.
49. Stone D.M., Hanson G.R., Gibb J.W. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 1987, 26:1657-1661.
50. Tai Y.F., Hoshi R., Brignell C.M., Cohen L., Brooks D.J., Curran H.V., Piccini P. Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA (" ecstasy" ): an 18F-Dopa PET study. Neuropsychopharmacology 2011, 36:735-743.
51. Tirmenstein M.A., Hu C.X., Scicchitano M.S., Narayanan P.K., McFarland D.C., Thomas H.C., Schwartz L.W. Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells. Toxicology In Vitro 2005, 19:471-479.
52. UNODC World drug report 2011, United Nations Office on Drugs and Crime, Vienna.
53. Wang S.T., Chen H.W., Sheen L.Y., Lii C.K. Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. Journal of Nutrition 1997, 127:2135-2141.
54. Wu C.W., Ping Y.H., Yen J.C., Chang C.Y., Wang S.F., Yeh C.L., Chi C.W., Lee H.C. Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis. Toxicology and Applied Pharmacology 2007, 220:243-251.